“The EU is in no hurry to get Sputnik V as a full-fledged commercial product into its market, fearing its high consumer properties, thanks to which it could slightly push back the products that the European bureaucracy is promoting at home,” Gintsburg said.
Sputnik V, developed by the Gamaleya Epidemiology and Microbiology Centre, received an emergency use authorization in Russia back in August. The vaccine is 91.6 percent effective against symptomatic COVID-19 and is 100 percent effective against severe cases.
The shot is based on the well-studied human adenovirus vector platform and has been approved for use in almost 60 countries. The EU’s medicines regulator launched a review of the Russian vaccine in early March.